Carney's response to whether Canada will retaliate on tariffs if it cannot reach a deal
CTV News' Rachel Aiello asks PM Mark Carney whether Canada will retaliate on tariffs if they cannot reach a deal with the U.S. by the August 1 deadline.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
19 minutes ago
- Globe and Mail
Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
to explore external market opportunities as a potential revenue source. Beta version to incorporate oncology targets, enhancing the accuracy and diversity of the PredicTcell model and potentially accelerating cancer immunotherapy development. to develop enhanced analytics and visualization tools, for the PredicTcell model to support its internal R&D teams. WARREN, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Tevogen ('Tevogen Bio Holdings Inc.' or 'Company') (Nasdaq: TVGN) today announced that its artificial intelligence initiative, is expanding its collaboration with Microsoft (Nasdaq: MSFT) and Databricks, to build the beta version of its foundational PredicTcell model. Powered by the Databricks Data Intelligence Platform and backed by their innovative engineering teams, has begun curating a dataset focused on oncology. The dataset, aggregated with the initial virology dataset. aims to improve upon the accuracy of the alpha version of PredicTcell model. This next phase of development builds on recently published international patent application (WO 2025/129197), which outlines novel machine learning systems for predicting immunologically active peptides, a critical step in developing targeted therapies for cancers and infectious diseases. 'We have been extremely fortunate to work with such great organizations like Microsoft and Databricks to build the alpha version of our foundational AI model,' said Mittul Mehta, Chief Information Officer and Head of 'Oncology represents one of the most impactful areas for AI in drug discovery, given the complexity of the disease and the limited availability of high-quality datasets.' Forward Looking Statements This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen's plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'possible,' 'potential,' 'goal,' 'opportunity,' 'project,' 'believe,' 'future,' and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Globe and Mail
19 minutes ago
- Globe and Mail
5 Reasons to Buy D-Wave Stock Like There's No Tomorrow
D-Wave (NYSE: QBTS) is up 120% in 2025, driven by momentum involving its Advantage2 system and a major capital raise. But with negative cash flow and dilution concerns, is it the next tech rocket or a risky bet? I'll break down the facts so you can decide before Wall Street catches up. *Stock prices used were the market prices of Aug. 4, 2025. The video was published on Aug. 5, 2025. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,039%* — a market-crushing outperformance compared to 181% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025 Rick Orford has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Rick Orford is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link, they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.
CTV News
19 minutes ago
- CTV News
When travellers can expect Concourse B to reopen at Calgary airport
Chris Miles, right, chief operating officer of the Calgary International Airport, speaks to members of the media on a tour of a closed concourse after parts of the domestic terminal building suffered hail and rain damage, in Calgary Aug. 6, 2024. (THE CANADIAN PRESS/Jeff McIntosh) A year after a powerful hailstorm damaged the Calgary International Airport, officials say work to repair and renovate the battered building is still underway. Concourse B was so badly damaged by the Aug. 5 thunderstorm that it had to be closed. After surveying the destruction, the decision was made to not only repair the concourse – built in 1966 – but to renovate it as well. 'It made sense to redevelop it with everything we know now about great design and great amenities,' said Calgary Airport Authority spokesperson Chris Miles. 'That means designing for universal access, better sustainability and making it more open, more welcoming and filled with natural light.' Among the changes are the removal of secure walkways and glassed-in sections left over from when Concourse B served as both a domestic and international terminal, which stopped in 2016. Now, the area is only for domestic flights. The renovation will allow for higher ceilings, roomier gate areas and unobstructed views of the Rocky Mountains. Officials say it took seven months to remove water-damaged infrastructure. Now, crews are replacing the roof. 'The work includes full replacement of approximately 60,000 square feet of roof, engineered with a resilient, sustainable design,' said a Tuesday news release. Miles says plans for the interior are still being finalized. 'That means new (information technology), new security systems, new HVAC systems that will be long-term more sustainable and cost-effective,' said a news B is expected to begin a graduated opening in 2027.
